Prima BioMed gets approval for IMP321 Phase I trial to treat solid tumours
Australian biotechnology firm Prima BioMed ’s German collaboration partner the Institute of Clinical Cancer Research has secured regulatory and ethical approvals for the initiation of a Phase I clinical trial (INSIGHT) of IMP321 to treat solid tumours… (Source: Drug Development Technology)
Source: Drug Development Technology - July 11, 2017 Category: Pharmaceuticals Source Type: news

Roche and Chugai Pharma report positive Phase III results of haemophilia A drug
Roche and UK-based Chugai Pharmaceutical have reported positive data from the Phase III HAVEN 1 clinical trial of emicizumab in patients suffering from haemophilia A. (Source: Drug Development Technology)
Source: Drug Development Technology - July 11, 2017 Category: Pharmaceuticals Source Type: news

Tailoring the Properties of New Compounds Using XRD Data Analysis
Understanding the make-up of crystalline structures is a vital aspect of the characterisation of new compounds, and can be regarded as an important first step towards the possibility of tailoring its properties. (Source: Drug Development Technology)
Source: Drug Development Technology - July 11, 2017 Category: Pharmaceuticals Source Type: news

Exelixis and BMS start Phase III combination trial for renal cell carcinoma
Exelixis and Bristol-Myers Squibb (BMS) have started the Phase III CheckMate 9ER clinical trial of Cabometyx (cabozantinib) combined with Opdivo (nivolumab) or both Opdivo and Yervoy (ipilimumab) to treat renal cell carcinoma (RCC). (Source: Drug Development Technology)
Source: Drug Development Technology - July 10, 2017 Category: Pharmaceuticals Source Type: news

Alnylam and Sanofi commence Phase III programme for haemophilia drug
Alnylam Pharmaceuticals and Sanofi Genzyme have commenced the Phase III clinical programme (ATLAS) of RNAi therapeutic fitusiran in patients with haemophilia A or B, with or without inhibitors. (Source: Drug Development Technology)
Source: Drug Development Technology - July 10, 2017 Category: Pharmaceuticals Source Type: news

Prexton begins Phase II trial of Foliglurax to treat Parkinson ’s disease
Swiss biopharmaceutical firm Prexton Therapeutics has begun a Phase II clinical trial (AMBLED) of Foliglurax for the treatment of patients suffering with Parkinson ’s disease (PD). (Source: Drug Development Technology)
Source: Drug Development Technology - July 10, 2017 Category: Pharmaceuticals Source Type: news

Inotek ’s trabodenoson shows no clinical advantage in Phase II FDC trial for glaucoma
Inotek Pharmaceuticals has reported top-line results from the Phase II fixed-dose combination (FDC) trial of trabodenoson and latanoprost in patients suffering from glaucoma. (Source: Drug Development Technology)
Source: Drug Development Technology - July 9, 2017 Category: Pharmaceuticals Source Type: news

Puma closes patient enrolment in Phase III breast cancer trial of neratinib
Puma Biotechnology has completed patient enrolment in the Phase III NALA trial of its lead drug candidate PB272 (neratinib) for the treatment of HER2-positive metastatic breast cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - July 9, 2017 Category: Pharmaceuticals Source Type: news

An Analysis of Antibodies Using Multi-Detector SEC Methodology
Antibodies' innate ability to direct their neutralisation attacks toward specific components in harmful agents has generated a large amount of interest within the pharmaceutical industry. (Source: Drug Development Technology)
Source: Drug Development Technology - July 9, 2017 Category: Pharmaceuticals Source Type: news

BeiGene commences dosing in Phase II trial of BGB-A317 to treat urothelial cancer
Global biotechnology company BeiGene has commenced dosing patients in a new Phase II trial of its investigational anti-PD-1 antibody, BGB-A317, in patients with urothelial cancer (UC), more commonly known as bladder cancer, in China. (Source: Drug Development Technology)
Source: Drug Development Technology - July 6, 2017 Category: Pharmaceuticals Source Type: news

Entasis and GARDP to evaluate zoliflodacin in Phase III trial for drug-resistant gonorrhea
US-based Entasis Therapeutics and the not-for-profit Global Antibiotic Research& Development Partnership (GARDP) have entered a partnership to develop a new treatment for drug-resistant gonorrhea. (Source: Drug Development Technology)
Source: Drug Development Technology - July 6, 2017 Category: Pharmaceuticals Source Type: news

Baxdela ™ (delafloxacin) for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Baxdela ™ (delafloxacin) is a fluoroquinolone antibiotic drug indicated for the treatment of adults with acute bacterial skin and skin structure infections (ABSSSI). The drug was discovered and developed by Melinta Therapeutics in partnership with Lig… (Source: Drug Development Technology)
Source: Drug Development Technology - July 6, 2017 Category: Pharmaceuticals Source Type: news

Trovagene selects PRA Health Sciences to conduct Phase lb/ll trial of PCM-075 for AML
US-based biotechnology company Trovagene has chosen global contract research organisation (CRO) PRA Health Sciences to carry out its Phase lb/ll clinical trial of PCM-075, a polo-like kinase 1 (PLK1) inhibitor, to treat patients with acute myeloid le … (Source: Drug Development Technology)
Source: Drug Development Technology - July 6, 2017 Category: Pharmaceuticals Source Type: news

Deals this week: Ritter Pharmaceuticals, Sienna Biopharmaceuticals, Exscientia
Ritter Pharmaceuticals has announced a public offering of class A units to raise $10m. (Source: Drug Development Technology)
Source: Drug Development Technology - July 6, 2017 Category: Pharmaceuticals Source Type: news

Aimmune begins patient enrolment in European Phase lll trial of AR101 for peanut allergy
US-based Aimmune Therapeutics has begun enrolling patients for the European Phase lll ARTEMIS (ARC010) clinical trial of its investigational biologic oral immunotherapy, AR101, to treat peanut allergy. (Source: Drug Development Technology)
Source: Drug Development Technology - July 5, 2017 Category: Pharmaceuticals Source Type: news